Cell Therapy For Parkinson's

Source: Fraunhofer-Gesellschaft
Article Date: 08 January 2007 - 0:00 PST

Summary:

To combat the decline in dopamine levels that occurs in patients with Parkinson's disease, researchers at NeuroProgen, a German biotechnology company, have developed a new drug on the basis of stem cells which is now being adapted to the regulatory standards of the pharmaceutical industry in partnership with the Fraunhofer Institute for Cell Therapy and Immunology IZI. Clinical trials of the cell-therapy drug could being in the next year as the first cell therapy employing neural stem cells.